US Patent No: 5,714,147

Number of patents in Portfolio can not be more than 2000

Hybrid immunoglobulins

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
GENENTECH, INC.SOUTH SAN FRANCISCO, CA1969

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Capon, Daniel J San Mateo, CA 61 3705
Lasky, Laurence A Sausalito, CA 36 1840

Cited Art Landscape

Patent Info (Count) # Cites Year
 
HOECHST AKTIENGESELLSCHAFT (1)
* 5,359,035 Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) 60 1992
 
Genentech, Inc. (1)
* 5,116,964 Hybrid immunoglobulins 529 1989
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (5)
* 2003/0219,436 Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein 17 2002
* 2003/0203,837 IG/OB fusions and uses thereof 2 2003
* 2004/0077,022 Modified peptides as therapeutic agents 17 2003
* 2006/0057,135 Mucosal vascular addressins and uses thereof 1 2005
8,633,305 Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules 0 2011
 
WYETH LLC (12)
7,704,503 Use of IL-17F in diagnosis and therapy of airway inflammation 0 2006
7,910,105 Methods for treating and preventing fibrosis 0 2006
* 2006/0257,403 Methods for treating and preventing fibrosis 8 2006
* 2008/0064,856 Methods for reducing protein aggregation 3 2007
7,744,890 Methods and compositions with reduced opalescence 0 2007
7,731,946 ) cell development and function 3 2007
* 2008/0269,132 USE OF LOW TEMPERATURE AND/OR LOW PH IN CELL CULTURE 35 2008
* 2009/0142,806 INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 0 2008
8,058,407 Purification of acidic proteins using ceramic hydroxyapatite chromatography 14 2009
* 2010/0113,751 PURIFICATION OF ACIDIC PROTEINS USING CERAMIC HYDROXYAPATITE CHROMATOGRAPHY 3 2009
* 2011/0039,780 PLATELET GLYCOPROTEIN IB ALPHA VARIANT FUSION POLYPEPTIDES AND METHODS OF USE THEREOF 0 2009
* 2011/0033,451 INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 1 2010
 
ALEXION PHARMACEUTICALS, INC. (1)
9,266,939 Compositions comprising natriuretic peptides and methods of use thereof 0 2011
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (3)
7,368,114 Fusion protein including of CD4 0 2002
* 2004/0265,306 Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4 0 2004
* 2009/0285,815 IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION 0 2008
 
EMERGENT PRODUCTIVE DEVELOPMENT SEATTLE, LLC. (1)
8,409,577 Single chain multivalent binding proteins with effector function 4 2007
 
AMYLIN PHARMACEUTICALS, INC. (1)
7,718,400 Methods of increasing lean tissue mass using OB protein compositions 0 2007
 
ITERATIVE THERAPEUTICS, INC. (6)
8,163,289 Methods and compositions involving polymeric immunoglobulin fusion proteins 0 2008
* 2008/0292,704 Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins 1 2008
7,897,729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors 3 2008
* 2009/0117,133 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS 3 2008
8,986,698 Method of using fusion proteins 0 2011
9,127,063 Nucleic acids related to fusion proteins 0 2013
 
The Rockefeller University (9)
6,429,290 OB polypeptides, modified forms and derivatives 9 1995
6,471,956 Ob polypeptides, modified forms and compositions thereto 7 1995
6,350,730 OB polypeptides and modified forms as modulators of body weight 6 1995
6,309,853 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof 31 1995
* 6,124,448 Nucleic acid primers and probes for the mammalian OB gene 1 1995
* 6,048,837 OB polypeptides as modulators of body weight 30 1995
7,544,492 OB polypeptides, modified forms and derivatives 3 2000
7,994,301 Modulators of body weight, corresponding nucleic acids and proteins 0 2009
8,173,793 Nucleic acids encoding modulators of body weight 0 2009
 
MERCK SHARP & DOHME CORP. (6)
7,713,521 MCP1 fusions 1 2006
* 2007/0036,750 MCP1 fusions 3 2006
7,972,591 Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions 1 2009
8,282,914 Method for treating atherosclerosis by administering human MCP1 fusions 1 2011
* 2011/0206,669 MCP1 FUSIONS 0 2011
8,524,217 MCP1-Ig fusion variants 0 2011
 
Recopharma AB (12)
8,034,351 Mucin fusion polypeptide vaccines, compositions and methods of use thereof 2 2003
* 2004/0001,844 Lewis Y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof 0 2003
* 2004/0002,585 Mucin fusion polypeptide vaccines, compositions and methods of use thereof 4 2003
7,638,323 Fusion proteins and methods of producing same 0 2003
* 2004/0137,580 Fusion proteins and methods of producing same 3 2003
7,658,919 adhesion and infection 0 2005
* 2006/0177,463 Compositions and methods for inhibiting H. pylori adhesion and infection 0 2005
* 2007/0184,063 Production of Proteins Carrying Oligomannose or Human-Like Glycans in Yeast and Methods of Use Thereof 2 2007
* 2007/0184,065 Compositions and Methods for Inhibiting Viral Adhesion 1 2007
* 2009/0181,041 Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof 2 2008
* 2009/0280,134 COMPOSITIONS AND METHODS FOR INHIBITING TOXIN A FROM CLOSTRIDIUM DIFFICILE 0 2009
* 2009/0280,104 COMPOSITIONS AND METHODS FOR INHIBITING SHIGA TOXIN AND SHIGA-LIKE TOXIN 0 2009
 
YALE UNIVERSITY (6)
6,924,359 Neovascular-targeted immunoconjugates 0 2000
7,858,092 Neovascular-targeted immunoconjugates 2 2005
* 2005/0214,298 Neovascular-targeted immunoconjugates 0 2005
8,071,104 Neovascular-targeted immunoconjugates 1 2010
* 2011/0117,114 Neovascular-Targeted Immunoconjugates 0 2010
8,388,974 Neovascular-targeted immunoconjugates 0 2011
 
BROWN UNIVERSITY (1)
* 2007/0117,981 Rhodium quinonoid catalysts 0 2006
 
Millennium Pharmaceuticals, Inc. (5)
7,803,904 Mucosal vascular addressing and uses thereof 0 1996
* 2002/0147,314 MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF 4 1997
* 2002/0172,679 Treatment of inflammatory bowel disease by inhibiting binding and/or signalling through alpha4beta7 and its ligands and MAdCAM 6 2002
8,277,808 Mucosal vascular addressins and uses thereof 0 2007
* 2007/0178,089 Mucosal vascular addressins and uses thereof 0 2007
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (8)
* 2010/0015,642 B7-H1 AND SURVIVIN IN CANCER 3 2007
* 2009/0215,084 B7-H1 AND B7-H4 IN CANCER 2 2007
8,039,589 B7-DC variants 7 2007
* 2009/0176,317 Soluble B7-H1 3 2008
* 2011/0020,325 METHODS FOR REDUCING GRANULOMATOUS INFLAMMATION 3 2009
8,747,833 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer 2 2011
8,273,864 Nucleic acid molecules encoding B7-DC variants 2 2011
8,460,927 B7-H1 antibodies and method of use 2 2011
 
Absorber AB (3)
7,897,328 Blood group antigens of different types for diagnostic and therapeutic applications 0 2007
* 2007/0224,652 Blood Group Antigens of Different Types for Diagnostic and Therapeutic Applications 0 2007
8,404,456 Blood group antigens of different types for diagnostic and therapeutic applications 0 2011
 
Trubion Pharmaceuticals (3)
7,754,209 Binding constructs and methods for use thereof 15 2003
* 2007/0059,306 B-cell reduction using CD37-specific and CD20-specific binding molecules 25 2006
* 2010/0279,932 BINDING CONSTRUCTS AND METHODS FOR USE THEREOF 12 2010
 
MICROMET AG (2)
7,332,168 Composition for the elimination of autoreactive B-cells 0 2001
* 2004/0072,749 Composition for the elimination of autoreactive b-cells 1 2003
 
TRUBION PHARMACEUTICALS, INC. (7)
* 2005/0238,646 Binding domain-immunoglobulin fusion proteins 64 2005
* 2005/0202,012 Binding domain-immunogloubulin fusion proteins 23 2005
* 2005/0202,023 Binding domain-immunoglobulin fusion proteins 61 2005
* 2005/0202,534 Binding domain-immunoglobulin fusion proteins 64 2005
* 2005/0186,216 Binding domain-immunoglobulin fusion proteins 27 2005
* 2005/0180,970 Binding domain-immunoglobulin fusion proteins 25 2005
* 2005/0175,614 Binding domain-immunoglobulin fusion proteins 61 2005
 
HANMI SCIENCE CO., LTD. (4)
7,736,653 Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier 10 2004
7,737,260 Protein complex using an immunoglobulin fragment and method for the preparation thereof 9 2004
* 2010/0255,014 Protein Complex Using An Immunoglobulin Fragment and Method For The Preparation Thereof 1 2010
8,110,665 Pharmaceutical composition comprising an immunoglobulin FC region as a carrier 9 2010
 
WYETH (14)
* 2003/0133,936 CD25markers and uses thereof 12 2002
* 2004/0016,010 IL-21 receptor knockout animal and methods of use thereof 21 2003
7,314,623 Methods and compositions for modulating T helper (Th) cell development and function 10 2003
* 2004/0136,954 Methods and compositions for modulating T helper (Th) cell development and function 5 2003
7,618,632 Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies 3 2004
* 2005/0014,224 GITR ligand and GITR ligand-related molecules and antibodies and uses thereof 11 2004
7,727,535 Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof 0 2004
* 2005/0089,888 Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof 0 2004
* 2006/0039,902 Antagonizing interleukin-21 receptor activity 43 2005
* 2006/0140,935 Platlet glycoprotein Ib alpha fusion polypeptides and methods of use thereof 0 2005
* 2006/0093,614 Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof 0 2005
* 2011/0033,483 SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION 12 2007
* 2008/0241,098 ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY 12 2007
* 2010/0080,809 GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF 0 2009
 
GENECRAFT, INC. (1)
* 2004/0058,445 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB 25 2002
 
Emergent Product Development Seattle, LLC (18)
* 2003/0133,939 Binding domain-immunoglobulin fusion proteins 122 2002
7,754,208 Binding domain-immunoglobulin fusion proteins 15 2002
7,829,084 Binding constructs and methods for use thereof 13 2003
* 2005/0136,049 Binding constructs and methods for use thereof 53 2003
8,106,161 Binding domain-immunoglobulin fusion proteins 3 2005
* 2005/0202,028 Binding domain-immunoglobulin fusion proteins 64 2005
8,333,966 CD37 immunotherapeutics and uses thereof 4 2009
* 2011/0171,208 CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF 10 2009
9,101,609 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof 0 2009
8,147,835 Binding domain-immunoglobulin fusion proteins 4 2009
* 2010/0034,820 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 11 2009
8,197,810 Binding domain-immunoglobulin fusion proteins 2 2010
8,188,237 Binding domain-immunoglobulin fusion proteins 2 2010
* 2011/0105,729 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 11 2010
* 2011/0091,461 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 11 2010
* 2011/0223,164 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 5 2011
8,853,366 Binding domain-immunoglobulin fusion proteins 0 2012
9,005,612 Binding domain-immunoglobulin fusion proteins 0 2012
 
THE JOHNS HOPKINS UNIVERSITY (7)
8,053,414 Methods of using B7-DC molecules to induce or enhance an immune response 7 2007
8,053,558 Dendritic cell co-stimulatory molecules 7 2007
* 2008/0226,662 Dendritic cell co-stimulatory molecules 14 2007
8,153,595 B7-DC variants immunogenic compositions and methods of use thereof 3 2008
* 2009/0042,292 B7-DC Variants 10 2008
8,445,447 B7-DC variants immunogenic compositions and methods of use thereof 0 2012
9,370,565 Dendritic cell co-stimulatory molecules 0 2013
 
ARNASON, BARRY G. (2)
7,511,121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors 7 2002
* 2003/0161,826 Polymeric immunoglobulin fusion proteins that target low-affinity fcyreceptors 41 2002
 
Genentech, Inc. (13)
* 6,994,856 ErbB4 receptor-specific neuregulin related ligands and uses therefor 2 1998
6,696,290 ErbB2 and ErbB4 Chimeric Heteromultimeric Adhesins 29 1999
7,101,851 IgE receptor antagonists 2 2001
7,084,109 FVIIa antagonists 10 2002
* 2003/0119,727 FVIIa antagonists 4 2002
7,164,002 FVIIa antagonists 0 2003
7,659,368 ErbB2 and ErbB3 chimeric heteromultimer adhesins 1 2003
* 2004/0138,417 Chimeric heteromultimer adhesins 12 2003
7,662,585 ErbB4 receptor-specific neuregulin related ligands and uses therefor 0 2004
* 2005/0136,467 ErbB4 receptor-specific neuregulin related ligands and uses therefor 0 2005
7,846,453 Methods of stimulating ErbB4 receptor phosphorylation 0 2006
* 2007/0081,994 Chimeric Heteromultimer Adhesins 5 2006
8,226,935 ErbB2 and ErbB3 chimeric heteromultimer receptors 0 2009
 
AMGEN INC. (36)
6,660,843 Modified peptides as therapeutic agents 204 1999
7,166,707 Modified peptides as therapeutic agents 14 2003
7,189,827 Modified peptides as therapeutic agents 15 2003
* 2004/0053,845 Modified peptides as therapeutic agents 3 2003
* 2004/0071,712 Modified peptides as therapeutic agents 2 2003
7,186,810 Modified peptides as therapeutic agents 3 2003
7,169,905 Modified peptides as therapeutic agents 2 2003
* 2004/0087,778 Modified peptides as therapeutic agents 11 2003
6,936,439 OB fusion protein compositions and methods 12 2003
8,044,174 Thrombopoietic compounds 2 2004
* 2005/0080,014 Thrombopoietic compounds 0 2004
7,208,577 Methods of increasing lean tissue mass using OB protein compositions 2 2005
* 2005/0176,107 Methods of increasing lean tissue mass using OB protein compositions 1 2005
7,112,659 OB fusion protein compositions and methods 4 2005
7,442,778 Modified Fc molecules 51 2005
* 2006/0140,934 Modified Fc molecules 11 2005
9,145,450 Thrombopoietic compounds 0 2006
* 2006/0234,307 Modified peptides as therapeutic agents 1 2006
8,008,453 Modified Fc molecules 6 2006
8,080,254 OB fusion protein compositions and methods 0 2006
* 2007/0020,284 OB fusion protein compositions and methods 0 2006
* 2007/0049,532 Modified peptides as therapeutic agents 0 2006
* 2007/0224,193 METHODS OF INCREASING LEAN TISSUE MASS USING OB PROTEIN COMPOSITIONS 0 2007
7,750,127 Modified Fc molecules 12 2008
7,750,128 Modified Fc molecules 13 2008
7,662,931 Modified Fc molecules 27 2008
7,655,764 Modified Fc molecules 16 2008
7,655,765 Modified Fc molecules 16 2008
7,645,861 Modified Fc molecules 14 2008
* 2009/0022,744 Modified Fc molecules 4 2008
* 2009/0012,272 Modified Fc molecules 4 2008
7,994,117 Thrombopoietic compounds 2 2009
* 2009/0186,822 Thrombopoietic Compounds 0 2009
9,114,175 Modified Fc molecules 0 2011
8,748,571 Thrombopoietic compounds 2 2011
8,618,044 Thrombopoietic compounds 2 2012
 
Cavit Sciences, Inc (1)
* 2007/0161,546 Methods and compositions for treatment of cancer 1 2006
 
MEDIMMUNE, LLC (1)
8,709,416 Compositions of PD-1 antagonists and methods of use 2 2011
 
GENETICS INSTITUTE, LLC (9)
7,189,400 Methods of treatment with antagonists of MU-1 7 2001
6,991,796 Platlet glycoprotein IBα fusion polypeptides and methods of use thereof 0 2002
7,198,789 Methods and compositions for modulating interleukin-21 receptor activity 10 2002
* 2003/0108,549 Methods and compositions for modulating interleukin-21 receptor activity 7 2002
7,049,128 Platelet glycoprotein Ib.alpha. fusion polypeptides and methods of use thereof 0 2003
7,705,123 MU-1, member of the cytokine receptor family 2 2007
* 2008/0167,241 MU-1, MEMBER OF THE CYTOKINE RECEPTOR FAMILY 3 2007
* 2009/0148,427 PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF USE THEREOF 0 2008
7,994,292 MU-1, member of the cytokine receptor family 0 2010
* Cited By Examiner